サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1772200

米国のラテラルフローアッセイ市場規模、シェア、動向分析レポート：製品別、用途別、技術別、最終用途別、セグメント予測、2025年～2033年

U.S. Lateral Flow Assay Market Size, Share & Trends Analysis Report By Product, By Application, By Technique, By End use, And Segment Forecasts, 2025 - 2033

出版日
ページ情報
英文 100 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.47円
米国のラテラルフローアッセイ市場規模、シェア、動向分析レポート：製品別、用途別、技術別、最終用途別、セグメント予測、2025年～2033年
出版日: 2025年06月30日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

米国のラテラルフローアッセイ市場動向：

米国のラテラルフローアッセイ市場規模は2024年に28億2,000万米ドルとなり、2033年には46億3,000万米ドルに達すると予測され、2025年から2033年までのCAGRは6.08%で成長します。

感染症の流行の高まりは、世界中の公衆衛生システムに甚大なプレッシャーを与えています。都市化の進展、相互接続性、抗菌薬耐性、気候変動の影響の高まりに伴い、専門家は感染症サーベイランス、予防、診断能力の強化が急務であると強調しています。感染症の世界の増加は、迅速な診断ソリューションを必要とするラテラル・フロー・アッセイ（LFA）市場を大きく牽引しています。米国疾病予防管理センター（CDC）によると、米国の結核患者は2022年の7,874人から2024年には1万347人に増加し、公衆衛生上の顕著な課題を反映しています。

蚊媒介性疾患検査分野は、西ナイルウイルス（WNV）、デング熱、チクングニア、ジカウイルス、マラリア、黄熱病などの蚊媒介性感染症の流行が増加していることから、大きな成長が予測されています。これらの感染症の増加により、特に流行しやすい地域では、迅速かつ効率的な診断ソリューションに対する需要が高まっています。米国疾病予防管理センター（CDC）によると、西ナイル・ウイルス（WNV）は米国で流行しており、48州すべてとコロンビア特別区で、主に夏から秋にかけて感染例が報告されています。2024年11月現在、CDCは1,466例のWNV感染者を記録しており、2022年には913例のヒト感染者が報告され、70％が神経侵襲性、30％が非神経侵襲性に分類されています。COVID-19やサル痘のような現在進行中の健康危機と並んで、蚊が媒介する疾病の負担が増加していることから、効果的な診断・監視対策の緊急性が強調されています。

公衆衛生の取り組みもまた、市場拡大において重要な役割を果たしています。CDCのインフルエンザ部門国際プログラムは、インフルエンザと闘うためのサーベイランス、パンデミック対策、調査、ワクチン接種プログラムに重点を置いています。さらに、全国郡市保健担当者協会は、インフルエンザの予防と対策において、地域の保健部門を支援しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国のラテラルフローアッセイ市場の変数、動向、および範囲

  • 市場イントロダクション/系統展望
  • 市場規模と成長見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
    • 市場機会分析
    • 市場課題分析
  • 米国のラテラルフローアッセイ市場分析ツール
    • ポーター分析
    • PESTEL分析

第4章 米国のラテラルフローアッセイ市場：製品推定・動向分析

  • 米国のラテラルフローアッセイ市場：製品変動分析
  • 製品別2024年および2033年
  • キットと試薬
  • ラテラルフローリーダー
    • ベンチトップリーダー
    • デジタルリーダー

第5章 米国のラテラルフローアッセイ市場：用途の推定・動向分析

  • 米国のラテラルフローアッセイ市場：用途変動分析
  • 用途別2024年および2033年
  • 臨床試験
    • 感染症検査
    • 心臓マーカー検査
    • 妊娠と生殖能力の検査
    • コレステロール検査/脂質プロファイル
    • 乱用薬物検査
    • その他の臨床検査
  • 獣医診断
  • 食品安全と環境試験
  • 医薬品開発と品質試験

第6章 米国のラテラルフローアッセイ市場：技術推定・動向分析

  • 米国のラテラルフローアッセイ市場：技術変動分析
  • 技術2024年および2033年
  • サンドイッチアッセイ
  • 競合アッセイ
  • マルチプレックス検出アッセイ

第7章 米国のラテラルフローアッセイ市場：最終用途の推定・動向分析

  • 米国のラテラルフローアッセイ市場：最終用途変動分析
  • 最終用途別2024年および2033年
  • 病院と診療所
  • 診断検査室
  • ホームケア
  • 製薬・バイオテクノロジー企業
  • その他の用途

第8章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 企業分類
  • 企業ヒートマップ分析
  • 企業プロファイル
    • Abbott
    • Bio-Rad Laboratories, Inc
    • Siemens Healthineers AG
    • BIOMERIEUX
    • BD
    • QIAGEN
    • QuidelOrtho Corporation
    • F. Hoffmann-La Roche
    • DH Life Sciences, LLC.
    • Quest Diagnostics
図表

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. lateral flow assay market, by region, 2018 - 2033 (USD Million)
  • Table 3 U.S. lateral flow assay market, by product, 2018 - 2033 (USD Million)
  • Table 4 U.S. lateral flow assay market, by technique, 2018 - 2033 (USD Million)
  • Table 5 U.S. lateral flow assay market, by application, 2018 - 2033 (USD Million)
  • Table 6 U.S. lateral flow assay market, by end-use, 2018 - 2033 (USD Million)

List of Figures

  • Fig. 1 U.S. lateral flow assay market segmentation
  • Fig. 2 Data analysis models
  • Fig. 3 Market formulation and validation
  • Fig. 4 Data validating & publishing
  • Fig. 5 Market research process
  • Fig. 6 Information procurement
  • Fig. 7 Primary research
  • Fig. 8 Value-chain-based sizing & forecasting
  • Fig. 9 QFD modelling for market share assessment
  • Fig. 10 Market formulation & validation
  • Fig. 11 Commodity flow analysis
  • Fig. 12 Market outlook
  • Fig. 13 Segment snapshot-1
  • Fig. 14 Segment snapshot-2
  • Fig. 15 Competitive landscape snapshot
  • Fig. 16 Market trends & outlook
  • Fig. 17 Porter's five force analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 U.S. lateral flow assay market: Product outlook key takeaways
  • Fig. 20 U.S. lateral flow assay market: Product movement analysis
  • Fig. 21 Kits & reagents market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Lateral flow readers market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Benchtop readers market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Digital readers market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 U.S. lateral flow assay market: Application outlook key takeaways
  • Fig. 26 U.S. lateral flow assay market: Application movement analysis
  • Fig. 27 Clinical testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Infectious disease testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Covid-19 market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 Mosquito borne disease testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 Malaria Testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Dengue Testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Zika Testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Chikungunya Testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Others market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Influenza testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Sexually transmitted infection testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 HIV testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 HPV testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Chlamydia testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 Gonorrhea testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Syphilis testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 Other STI testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Hepatitis market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 Tuberculosis market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Other infectious diseases market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Cardiac marker testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 Troponin I and t testing
  • Fig. 49 CK-MB testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 BNP and NT-PROBNP testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Myoglobin testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 D-dimer testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Other cardiac marker tests market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 Pregnancy & fertility testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Pregnancy testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 56 Fertility testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Cholesterol testing/lipid profile market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 58 Drugs of abuse testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Other clinical tests market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 60 Veterinary diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 Food safety & environment testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 62 Drug development & quality testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 U.S. lateral flow assay market: Technique outlook key takeaways
  • Fig. 64 U.S. lateral flow assay market: Technique movement analysis
  • Fig. 65 Sandwich assays market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 66 Competitive assays market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 67 Multiplex detection assays market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 U.S. Lateral Flow Assay market: Test Type outlook key takeaways
  • Fig. 69 U.S. Lateral Flow Assay market: Test Type movement analysis
  • Fig. 70 Lateral flow immunoassay market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 71 Nucleic acid lateral flow assay market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 U.S. Lateral Flow Assay market: End-use outlook key takeaways
  • Fig. 73 U.S. Lateral Flow Assay market: End-use movement analysis
  • Fig. 74 Hospitals & clinics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 75 Diagnostic laboratories market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 76 Home care market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 77 Pharmaceutical & biotechnology companies market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 78 Other End-use market estimates and forecasts, 2021 - 2033 (USD Million)
目次
Product Code: GVR-4-68040-646-5

U.S. Lateral Flow Assay Market Trends:

The U.S. lateral flow assay market size was valued at USD 2.82 billion in 2024 and is projected to reach USD 4.63 billion by 2033, growing at a CAGR of 6.08% from 2025 to 2033. The rising prevalence of infectious diseases places immense pressure on public health systems worldwide. With increasing urbanization, interconnectivity, antimicrobial resistance, and the rising impact of climate change, experts stress the urgent need for enhanced infectious disease surveillance, prevention, and diagnostic capabilities. The global rise in infectious diseases significantly drives the lateral flow assays (LFA) market by necessitating rapid diagnostic solutions. According to the Centers for Disease Control and Prevention (CDC), tuberculosis (TB) cases in the U.S. increased from 7,874 in 2022 to 10,347 in 2024, reflecting a notable public health challenge.

The mosquito-borne disease testing segment is projected to experience significant growth due to the rising prevalence of mosquito-borne infections, including West Nile virus (WNV), dengue, chikungunya, Zika virus, malaria, and yellow fever. The increasing incidence of these diseases has heightened the demand for rapid and efficient diagnostic solutions, particularly in regions prone to outbreaks. According to the Centers for Disease Control and Prevention (CDC), West Nile virus (WNV) has become endemic in the U.S., with cases reported in all 48 contiguous states and the District of Columbia, predominantly during the summer and fall months. As of November 2024, the CDC recorded 1,466 cases of WNV, while in 2022, 913 human cases were reported, with 70% classified as neuroinvasive and 30% as non-neuroinvasive. The increasing burden of mosquito-borne diseases, alongside ongoing health crises such as COVID-19 and monkeypox, underscores the urgent need for effective diagnostic and surveillance measures.

Public health initiatives also play a crucial role in market expansion. The CDC's Influenza Division International Program focuses on surveillance, pandemic preparedness, research, and vaccination programs to combat influenza. Additionally, the National Association of County and City Health Officials supports local health departments in influenza prevention and control.

U.S. Lateral Flow Assay Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. lateral flow assay market report based on product, application, technique, and end use:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Kits & Reagents
  • Lateral Flow Readers
  • Benchtop Readers
  • Digital Readers
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Clinical Testing
    • Infectious Disease Testing
    • COVID-19
    • Mosquito Borne Disease Testing
    • Malaria Testing
    • Dengue Testing
    • Zika Testing
    • Chikungunya Testing
    • Others
    • Influenza Testing
    • Sexually Transmitted Infection Testing
    • HIV Testing
    • HPV Testing
    • Chlamydia Testing
    • Gonorrhea Testing
    • Syphilis Testing
    • Other STI Testing
    • Hepatitis
    • Tuberculosis
    • Other Infectious Diseases
    • Cardiac Marker Testing
    • Troponin I and T Testing
    • CK-MB Testing
    • BNP and NT-Probnp Testing
    • Myoglobin Testing
    • D-Dimer Testing
    • Other Cardiac Marker Tests
    • Pregnancy & Fertility Testing
    • Pregnancy Testing
    • Fertility Testing
    • Cholesterol Testing/Lipid Profile
    • Drugs of Abuse Testing
    • Other Clinical Tests
  • Veterinary Diagnostics
  • Food Safety & Environment Testing
  • Drug Development & Quality Testing
  • Technique Outlook (Revenue, USD Million, 2021 - 2033)
  • Sandwich Assays
  • Competitive Assays
  • Multiplex Detection Assays
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Home Care
  • Pharmaceutical & Biotechnology Companies
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Lateral Flow Assay Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
      • 3.3.1.1. Increasing prevalence of infectious diseases
      • 3.3.1.2. Technological advancements in lateral flow
      • 3.3.1.3. Growing adoption in homecare settings
    • 3.3.2. Market Restraints Analysis
      • 3.3.2.1. Stringent Regulations
    • 3.3.3. Market Opportunities Analysis
      • 3.3.3.1. Growing demand for Point-of-Care (POC) Testing
      • 3.3.3.2. Expanding applications beyond healthcare
    • 3.3.4. Market Challenges Analysis
      • 3.3.4.1. Product Recalls
  • 3.4. U.S. Lateral Flow Assay Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. U.S. Lateral Flow Assay Market: Product Estimates & Trend Analysis

  • 4.1. U.S. Lateral Flow Assay Market: Product Movement Analysis
  • 4.2. U.S. Lateral Flow Assay Market Estimates and Forecasts, by Product 2024 & 2033 (USD Million)
  • 4.3. Kits & Reagents
    • 4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4. Lateral Flow Readers
    • 4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.2. Benchtop Readers
      • 4.4.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.3. Digital Readers
      • 4.4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Lateral Flow Assay Market: Application Estimates & Trend Analysis

  • 5.1. U.S. Lateral Flow Assay Market: Application Movement Analysis
  • 5.2. U.S. Lateral Flow Assay Market Estimates and Forecasts, by Application 2024 & 2033 (USD Million)
  • 5.3. Clinical Testing
    • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.3.2. Infectious Disease Testing
      • 5.3.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.3.2.2. COVID-19
        • 5.3.2.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.3.2.3. Mosquito Borne Disease Testing
        • 5.3.2.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 5.3.2.3.2. Malaria Testing
          • 5.3.2.3.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 5.3.2.3.3. Dengue Testing
          • 5.3.2.3.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 5.3.2.3.4. Zika Testing
          • 5.3.2.3.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 5.3.2.3.5. Chikungunya Testing
          • 5.3.2.3.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 5.3.2.3.6. Others
          • 5.3.2.3.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.3.2.4. Influenza Testing
        • 5.3.2.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.3.2.5. Sexually Transmitted Infection Testing
        • 5.3.2.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 5.3.2.5.2. HIV Testing
          • 5.3.2.5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 5.3.2.5.3. HPV Testing
          • 5.3.2.5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 5.3.2.5.4. Chlamydia Testing
          • 5.3.2.5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 5.3.2.5.5. Gonorrhea Testing
          • 5.3.2.5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 5.3.2.5.6. Syphilis Testing
          • 5.3.2.5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 5.3.2.5.7. Other STI Testing
          • 5.3.2.5.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.3.2.6. Hepatitis
        • 5.3.2.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.3.2.7. Tuberculosis
        • 5.3.2.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.3.2.8. Other Infectious Diseases
        • 5.3.2.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.3.3. Cardiac Marker Testing
      • 5.3.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.3.3.2. Troponin I and T Testing
        • 5.3.3.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.3.3.3. CK-MB Testing
        • 5.3.3.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.3.3.4. BNP and NT-Probnp Testing
        • 5.3.3.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.3.3.5. Myoglobin Testing
        • 5.3.3.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.3.3.6. D-Dimer Testing
        • 5.3.3.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.3.3.7. Other Cardiac Marker Tests
        • 5.3.3.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.3.4. Pregnancy & Fertility Testing
      • 5.3.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.3.4.2. Pregnancy Testing
        • 5.3.4.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.3.4.3. Fertility Testing
        • 5.3.4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.3.5. Cholesterol Testing/Lipid Profile
      • 5.3.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.3.6. Drugs of Abuse Testing
      • 5.3.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.3.7. Other Clinical Tests
      • 5.3.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Veterinary Diagnostics
    • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Food Safety & Environment Testing
    • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Drug Development & Quality Testing
    • 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Lateral Flow Assay Market: Technique Estimates & Trend Analysis

  • 6.1. U.S. Lateral Flow Assay Market: Technique Movement Analysis
  • 6.2. U.S. Lateral Flow Assay Market Estimates and Forecasts, by Technique 2024 & 2033 (USD Million)
  • 6.3. Sandwich Assays
    • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. Competitive Assays
    • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Multiplex Detection Assays
    • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Lateral Flow Assay Market: End Use Estimates & Trend Analysis

  • 7.1. U.S. Lateral Flow Assay Market: End-use Movement Analysis
  • 7.2. U.S. Lateral Flow Assay Market Estimates and Forecasts, by End-use 2024 & 2033 (USD Million)
  • 7.3. Hospitals & Clinics
    • 7.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4. Diagnostic Laboratories
    • 7.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Home Care
    • 7.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Pharmaceutical & Biotechnology Companies
    • 7.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Other End-use
    • 7.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Abbott
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Bio-Rad Laboratories, Inc
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Siemens Healthineers AG
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. BIOMERIEUX
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. BD
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. QIAGEN
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. QuidelOrtho Corporation
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. F. Hoffmann-La Roche
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. DH Life Sciences, LLC.
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Quest Diagnostics
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives